Elkins-Sinn GMP deviations in injectables manufacturing, packaging result in FDA warning letter.
ELKINS-SINN GMP DEVIATIONS FOR INJECTABLES RESULT IN WARNING LETTER from FDA July 14 citing 10 violations of current Good Manufacturing Practices at the Wyeth-Ayerst injectable drugs manufacturing facilities in Cherry Hill, N.J. FDA inspectors were on site at the facilities March 30 for a pre-approval inspection. Based on the warning letter, inspectors continued to evaluate the facilities on site at least until May 4.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth